Clinical trial NCT04402554: Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis
Official title: Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Keywords: Cannabis
Cannabis/therapeutic use
Cannabis/therapy
Medical Marijuana
Chronic Pain
Rheumatic Diseases
Arthritis, Rheumatoid
Spondylitis, Ankylosing
Arthritis, Psoriatic
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2020-05-27
Enrollment: 501
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with Chronic Inflammatory Rheumatism, whether rheumatoid arthritis or spondyloarthritis, seen in consultation in the department of Rheumatology

Brief summary: Patients with inflammatory rheumatism very often have residual pain that is not easily relieved by conventional treatments. They can then use non-drug methods, such as physiotherapy, hypnosis or even cannabis.

The aim of this study is to assess the percentage of patients who use cannabis to better relieve their pain or anxiety in chronic inflammatory rheumatism.

Detailed description: Thanks to a better understanding of the pathophysiological mechanisms of inflammatory rheumatism, rheumatology has known for several decades a growth in its therapeutic arsenal (csDMARDs, bDMARDs, tDMARDs). rheumatism control has thus been optimized.

however, patients very often keep pain, anxiety, residual fatigue, poorly controlled by our conventional therapies. patients then turn to non-drug therapies, among which the use of cannabis.

endocannabinoids have an analgesic and anti-inflammatory action recognized in pre-clinical trials. however, investigators currently lack the data to authorize its use in clinical rheumatology.

the aim of this study is to determine the prevalence of cannabis users in patients with rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis in our unit. as a second intention, investigators will refine the consumption characteristics. Investigators will also look for possible risk factors for consumption (sensitivity to pain, catastrophism, standard of living, anxiety, depression, rheumatic activity and quality of life).

Eligibility criteria: Inclusion Criteria:

* Rheumatoid Arthritis (ACR 2010 Criteria)
* Ankylosing Spondylitis (New york or ASAS criteria)
* Psoriatic Arthritis (CASPAR criteria)

Exclusion Criteria:

* Patient unable to complete questionnaires or unable to express informed consent
* Guardianship, trusteeship, deprivation of liberties, safeguard of justice

Primary outcomes:
measure: prevalence of cannabis use in patients with chronic inflammatory rheumatic conditions
timeFrame: Day 0
Secondary outcomes:
measure: Percentage of patients with problematic cannabis use
timeFrame: Day 0
measure: Assessing the association between cannabis use and disease activity of spondylitis ankylosing
timeFrame: Day 0
measure: Assessing the association between cannabis use and disease activity of rheumatoid arthritis / psoriatic arthritis
timeFrame: Day 0
measure: Assessing the association between cannabis use and functional disability
timeFrame: Day 0
measure: Assessing the association between cannabis use and Anxiety/Depression
timeFrame: Day 0
measure: Assessing the association between cannabis use and pain catastrophism
timeFrame: Day 0
measure: Assessing the association between cannabis use and social vulnerability
timeFrame: Day 0
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: Chu Clermont Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Sylvain Mathieu
role: PRINCIPAL_INVESTIGATOR
References: